Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/11531/49372
Título : Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer
Autor : Núñez Torres, Rocío
Martín, Miguel
García-Saénz, Jose Angel
Rodrigo Faus, María
del Monte-Millán, María
Tejera Pérez, Hugo
Pita, Guillermo
de la Torre Montero, Julio César
Pinilla, Karen Andrea
Herráez, Belén
Peiró-Chova, Lorena
Bermejo, Begoña
Lluch, Ana
González-Neira, Anna
Fecha de publicación :  1
Resumen : Describimos una asociación genética en la alopecia capilar producida por quimioterapia.
Importance Persistent chemotherapy-induced alopecia (pCIA) has been recently described in patients with breast cancer and in its most severe form occurs in up to 10% of these patients. Genetic risk factors associated with pCIA have not been adequately explored. Objective To identify genetic variants associated with pCIA. Design, Setting, and Participants In this genetic association study, 215 women with breast cancer treated with docetaxel-based chemotherapy with a follow-up of 1.5 to 10 years after the end of the treatment were recruited retrospectively through 3 hospital oncology units across Spain between 2005 and 2018. Severe pCIA was defined as lack of scalp hair recovery (Common Terminology Criteria for Adverse Events, version 3.0, grade 2) 18 months or more after the end of treatment. Patients with grade 2 pCIA were selected as cases, and those with no sign of residual alopecia 12 months after the end of docetaxel treatment were selected as controls. A genome-wide association study in a discovery phase was conducted, and logistic regression was used to identify variants associated with the risk to develop this adverse effect. The validity of the association was addressed through a replication phase. Exposures Docetaxel-based chemotherapy. Main Outcomes and Measures Genotypes of single-nucleotide variants associated with pCIA. Results In total, 215 women with breast cancer (median age, 51.6 years; interquartile range, 44-60 years) were recruited (173 patients for the discovery phase and 42 patients for the replication phase). In the discovery phase, ABCB1 genetic variants were associated with risk to develop pCIA. In particular, single-nucleotide variation rs1202179, a regulatory variant located in an enhancer element that interacts with the ABCB1 promoter, was associated with the occurrence of pCIA. This finding was validated in the replication cohort (combined odds ratio, 4.05; 95% CI, 2.46-6.67; P = 3.946 × 10−8). This variant is associated with ABCB1 mRNA expression, and the risk allele was associated with decreased ABCB1 expression levels (P = 1.64 × 10−20). Conclusions and Relevance This is the first study, to our knowledge, that identifies an association between a regulatory variant in the ABCB1 gene and the occurrence of pCIA in patients with breast cancer who were treated with docetaxel-based therapies. This finding suggests an important insight into the biological mechanisms underlying pCIA and opens the opportunity to explore personalized treatment of these patients.
Descripción : Artículos en revistas
URI : 10.1001/jamadermatol.2020.1867
ISSN : 2168-6084
Aparece en las colecciones: Artículos

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
JAMA_alopecia.PNG240,3 kBimage/pngVisualizar/Abrir     Request a copy


Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.